AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial products and therapeutic pipeline.
AIVITA’s technologies include a patient-specific immunotherapy for the treatment of advanced cancers. The treatment, autologous dendritic cells loaded with autologous irradiated tumor cells, directs the patient’s own immune system to seek out and destroy the very cells responsible for the growth and spread of the disease. The technology is currently being commercialized for melanoma in Japan, and is the subject of two US-based Phase 2 clinical trials for ovarian cancer and glioblastoma. The company is also developing an immune monitoring technology to be used in conjunction with its immunotherapy approach. The technique uses biomarker identification to provide physicians with an accurate prediction of how the patient will respond to treatment.
AIVITA Biomedical is also leveraging it’s proprietary capabilities and know-how to develop innovative commercial products, beginning with an anti-aging skincare technology containing more skin-relevant active ingredients than any other product. The clinically-proven technology includes growth factors captured from skin stem cells, the very cells responsible for the maintenance and renewal of young skin. All proceeds from the sale of AIVITA’s skincare products support the treatment of ovarian and brain cancer patients.